1 reports of this reaction
4.5% of all OCTINOXATE AND TITANIUM DIOXIDE reports
#18 most reported adverse reaction
RASH ERYTHEMATOUS is the #18 most commonly reported adverse reaction for OCTINOXATE AND TITANIUM DIOXIDE, manufactured by Noxell. There are 1 FDA adverse event reports linking OCTINOXATE AND TITANIUM DIOXIDE to RASH ERYTHEMATOUS. This represents approximately 4.5% of all 22 adverse event reports for this drug.
Patients taking OCTINOXATE AND TITANIUM DIOXIDE who experience rash erythematous should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RASH ERYTHEMATOUS is moderately reported among OCTINOXATE AND TITANIUM DIOXIDE users, representing a notable but not dominant share of adverse events.
In addition to rash erythematous, the following adverse reactions have been reported for OCTINOXATE AND TITANIUM DIOXIDE:
The following drugs have also been linked to rash erythematous in FDA adverse event reports:
RASH ERYTHEMATOUS has been reported as an adverse event in 1 FDA reports for OCTINOXATE AND TITANIUM DIOXIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
RASH ERYTHEMATOUS accounts for approximately 4.5% of all adverse event reports for OCTINOXATE AND TITANIUM DIOXIDE, making it a notable side effect.
If you experience rash erythematous while taking OCTINOXATE AND TITANIUM DIOXIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.